Semax (heptapeptide)
Not an FDA-approved drug. FDA lists Semax among bulk substances that may present significant safety risks in compounding and notes potential immunogenicity from aggregation and peptide-related impurities.
Current sourceSemax
Small human studies, regional clinical use, and unresolved U.S. safety questions
Semax is a synthetic ACTH-derived heptapeptide studied mainly in Russia for neurologic uses. It is not an FDA-approved drug. Published human research includes small imaging studies and a non-blinded rehabilitation study after ischemic stroke; these do not establish general cognitive enhancement or support self-directed use.
Editorial status
This page aggregates regulatory documents and published human research. Its claims, citations, populations, and limitations received an independent editorial evidence check. Last editorial audit: .
It has not been medically reviewed by a clinician. It provides general education, not diagnosis, treatment, dosing instructions, or advice for an individual. Use the product-specific official information and consult a qualified clinician or pharmacist for personal decisions.
Product and regulatory distinctions
A compound name is not one interchangeable set of instructions. Product, formulation, indication, labeling, and jurisdiction matter.
Semax-related compounded products
FDA reviewed Semax free base and acetate for possible 503A-list consideration in 2026; that review is not an FDA approval of a finished drug product.
Current sourceClaim-by-claim evidence map
Each finding is tied to the population and product actually studied. Trial results are not personal predictions.
Semax has been studied during rehabilitation after ischemic stroke.
- Population
- 110 people in early or later rehabilitation after ischemic stroke in a Russian clinical study.
- Finding
- The investigators reported higher plasma BDNF and better Barthel-index improvement in Semax subgroups.
- Limits
- The publication describes subgroup comparisons rather than a large blinded, placebo-controlled trial; rehabilitation timing and other differences limit causal interpretation and international generalizability.
An acute Semax study detected differences in resting-state brain-network imaging.
- Population
- 24 healthy volunteers: 14 received intranasal Semax and 10 received placebo.
- Finding
- Resting-state fMRI showed a difference in the volume of a default-mode-network subcomponent shortly after administration.
- Limits
- This small imaging experiment did not demonstrate improved memory, attention, daily function, or treatment of a disorder; an imaging signal is not a clinical benefit.
Semax and Selank produced distinguishable short-term connectivity patterns in another imaging study.
- Population
- 52 healthy participants who received Semax, Selank, or placebo for resting-state fMRI comparisons.
- Finding
- Investigators reported treatment-related differences in functional connectivity involving the amygdala and temporal regions.
- Limits
- The study measured acute surrogate imaging outcomes, not durable cognitive performance, disease outcomes, or long-term safety.
What this evidence does not answer
- No large, independently replicated international trial establishes Semax as a cognitive enhancer in healthy people.
- Human safety, immunogenicity, product comparability, and long-term outcomes remain poorly characterized in the accessible literature.
- Stroke-rehabilitation findings should not be generalized to prevention, acute stroke treatment, traumatic brain injury, ADHD, anxiety, or everyday focus.
Useful information to organize between visits
- The exact product, chemical form, manufacturer, and lot
- Any quality documentation addressing identity, purity, aggregation, sterility, and endotoxin as applicable
- The reason it is being considered and whether that claim comes from a human clinical outcome or a surrogate measure
- Symptoms or changes with onset, duration, severity, and concurrent substances
- Questions for a neurologist, pharmacist, or other appropriately licensed clinician
Questions to bring to a clinician or pharmacist
- 1.Does any human evidence directly match the condition or outcome I am concerned about?
- 2.What established diagnostic or treatment options should be considered first?
- 3.What is known—and not known—about interactions and immunogenicity?
- 4.How should a suspected adverse event or product-quality concern be reported?
Primary sources
- Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety RisksU.S. Food and Drug Administration · Published 2026 · Accessed July 12, 2026
- July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting materialsU.S. Food and Drug Administration · Published 2026 · Accessed July 12, 2026
- The efficacy of Semax in patients at different stages of ischemic-stroke rehabilitationZhurnal Nevrologii i Psikhiatrii via PubMed · Published 2018 · Accessed July 12, 2026
- Effects of Semax on the Default Mode Network of the BrainBulletin of Experimental Biology and Medicine via PubMed · Published 2018 · Accessed July 12, 2026
- Functional Connectomic Approach to Studying Selank and Semax EffectsBulletin of Experimental Biology and Medicine via PubMed · Published 2020 · Accessed July 12, 2026
Turn scattered notes into a useful treatment history
Dosi organizes timing, locations, symptoms, reminders, and questions for your next appointment. It does not prescribe or replace your care team.
Start tracking free